Associate Principal Scientist, Mixed Modality Product Development
Merck Sharp & Dohme is hiring for Associate Principal Scientist, Mixed Modality Product Development in USA - New Jersey - Rahway. Staff level, $142k–$224k a year stated. First seen November 4, 2026; open as of November 12, 2026. Jobs taken straight from company career pages — no aggregator in between.
With Destava: How well do you fit? · Tailor my résumé · Write a cover letter
- Company
- Merck Sharp & Dohme
- Where
- USA - New Jersey - Rahway
- Level
- Staff
- Pay stated
- $142k–$224k a year
- First seen
- November 4, 2026
- Listed via
- Workday
What the posting says
Job Description Job Description: The Mixed Modalities team within Sterile Product Development is responsible for developing parenteral dosage forms (injections, implants, inhaled, ocular) for small, intermediate, and large molecules from preclinical toxicology studies to commercialization. Our development teams ensure robust composition, primary packaging/device, and process selection through deep fundamental understanding and characterization such that the process is scalable without compromising stability, safety, efficacy, and delivery. During development, we leverage smart experimental…
Read more and apply on Merck Sharp & Dohme's site
More jobs like this
Biomedical Engineer
Save to applyBiomedical Engineer (Clinical Specialist)
Save to applypostdoctoral fellow
Save to applyProcess Development Engineer I, Bioreactor Scale-Up & Development
Save to apply
See all 20 Bioengineers and Biomedical Engineers jobs in New York
A search agent finds the jobs this list misses: the ones that mean the same without the same words. Have Destava watch for associate principal scientist, mixed modality product development jobs in USA - New Jersey - Rahway, new matches every morning on your own account.
This page includes information from the O*NET 31.0 Database by the U.S. Department of Labor, Employment and Training Administration (USDOL/ETA). Used under the CC BY 4.0 license. O*NET® is a trademark of USDOL/ETA.